Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.

NIL

Jahr

Publikationsjahr
2022

Link

Zur Publikation (externer Server)
https://doi.org/10.3389/fimmu.2022.852563

Tags

Forschungsthemen
Multiple SkleroseMS BehandlungNeuroimmunologie
NIL2022